The cleft width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The dental arch length at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The alveolar width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The dental arch width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Mean lesion depth of the SDF test groups and the SDF-free group at baseline and post-cycling time points. by Suphanida Kaewkamchai (19762172)

Mean mineral density of the SDF test groups and the SDF-free group at baseline and post-cycling time points. by Suphanida Kaewkamchai (19762172)

Gene co-expression network analysis of the GSE263867 dataset. by Yaping Yuan (2734228)

Characteristics of JIA patients. by Yasmine Makhlouf (17409866)

“…Following biologic therapy, growth delay decreased to 8% and impaired growth to 36.8%. Patients with systemic JIA showed lower changes in growth parameters compared to others, and no significant differences were observed between different biologic drugs. …”

List of excluded articles. by Yasmine Makhlouf (17409866)

“…Following biologic therapy, growth delay decreased to 8% and impaired growth to 36.8%. Patients with systemic JIA showed lower changes in growth parameters compared to others, and no significant differences were observed between different biologic drugs. …”

Multiple comparisons after ANOVA(CR10). by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Homogeneity test of CR10. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Illustration of the fNIRS device worn. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Analysis of variance of HbO₂ in bilateral PFC. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

fNIRS equipment coordinates. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Changes of muscle oxygen saturation. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Analysis of variance of CR10. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Placement on the forehead. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

IMW intervention plan design. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Patients outcome. by Loïc Duron (6433634)

“…Reliance on temporal-artery biopsy fell (17% vs 91%; p < 0.01), owing to a four-fold rise in diagnostic MRI use. Mean total medical costs decreased by €814 per patient (€3672 ± 2861 vs €4486 ± 3193), although this difference did not reach statistical significance (p = 0.23).…”

Table 1_Pre-COVID era pediatric disease incidence in Kazakhstan: regional panel data analysis of multiple disease groups (2010–2019).xlsx by Nurlan Smagulov (21510632)

“…Other variables with variance inflation factors ≥5 were excluded to mitigate multicollinearity.</p>Results<p>Respiratory diseases showed the highest mean incidence (57,329.86 per 100,000), with significant regional variation. …”